WO2020123753A3 - Anellosomes pour l'administration de modalités thérapeutiques intracellulaires - Google Patents

Anellosomes pour l'administration de modalités thérapeutiques intracellulaires Download PDF

Info

Publication number
WO2020123753A3
WO2020123753A3 PCT/US2019/065874 US2019065874W WO2020123753A3 WO 2020123753 A3 WO2020123753 A3 WO 2020123753A3 US 2019065874 W US2019065874 W US 2019065874W WO 2020123753 A3 WO2020123753 A3 WO 2020123753A3
Authority
WO
WIPO (PCT)
Prior art keywords
anellosomes
therapeutic modalities
intracellular therapeutic
delivering intracellular
delivering
Prior art date
Application number
PCT/US2019/065874
Other languages
English (en)
Other versions
WO2020123753A2 (fr
Inventor
Erica Gabrielle WEINSTEIN
Avak Kahvejian
Simon Delagrave
Nathan Lawrence YOZWIAK
Kevin James LEBO
Fernando Martin DIAZ
Dhananjay Maniklal NAWANDAR
Ryan D. TEDSTONE
Jared David PITTS
Original Assignee
Flagship Pioneering Innovations V, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2021533523A priority Critical patent/JP2022514501A/ja
Priority to MX2021006941A priority patent/MX2021006941A/es
Priority to CA3119339A priority patent/CA3119339A1/fr
Priority to KR1020217021774A priority patent/KR20210131308A/ko
Priority to CN201980091151.3A priority patent/CN114127302A/zh
Priority to BR112021009282-0A priority patent/BR112021009282A2/pt
Application filed by Flagship Pioneering Innovations V, Inc. filed Critical Flagship Pioneering Innovations V, Inc.
Priority to EP19836313.7A priority patent/EP3894567A2/fr
Priority to AU2019396516A priority patent/AU2019396516A1/en
Priority to US17/413,123 priority patent/US20220040117A1/en
Publication of WO2020123753A2 publication Critical patent/WO2020123753A2/fr
Publication of WO2020123753A3 publication Critical patent/WO2020123753A3/fr
Priority to IL283771A priority patent/IL283771A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

Cette invention concerne, d'une manière générale, des anellosomes ainsi que des compositions et leurs utilisations.
PCT/US2019/065874 2018-12-12 2019-12-12 Anellosomes pour l'administration de modalités thérapeutiques intracellulaires WO2020123753A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
MX2021006941A MX2021006941A (es) 2018-12-12 2019-12-12 Anelosomas para suministrar modalidades terapéuticas intracelulares.
CA3119339A CA3119339A1 (fr) 2018-12-12 2019-12-12 Anellosomes pour l'administration de modalites therapeutiques intracellulaires
KR1020217021774A KR20210131308A (ko) 2018-12-12 2019-12-12 세포내 치료 양식을 운반하기 위한 아넬로좀
CN201980091151.3A CN114127302A (zh) 2018-12-12 2019-12-12 用于递送细胞内治疗方式的指环体
BR112021009282-0A BR112021009282A2 (pt) 2018-12-12 2019-12-12 anelossomos para entrega de modalidades terapêuticas intracelulares
JP2021533523A JP2022514501A (ja) 2018-12-12 2019-12-12 細胞内治療モダリティを送達するためのアネロソーム
EP19836313.7A EP3894567A2 (fr) 2018-12-12 2019-12-12 Anellosomes pour l'administration de modalités thérapeutiques intracellulaires
AU2019396516A AU2019396516A1 (en) 2018-12-12 2019-12-12 Anellosomes for delivering intracellular therapeutic modalities
US17/413,123 US20220040117A1 (en) 2018-12-12 2019-12-12 Anellosomes for delivering intracellular therapeutic modalities
IL283771A IL283771A (en) 2018-12-12 2021-06-07 Analosomes for the delivery of intracellular therapeutic modalities

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862778866P 2018-12-12 2018-12-12
US201862778851P 2018-12-12 2018-12-12
US62/778,851 2018-12-12
US62/778,866 2018-12-12

Publications (2)

Publication Number Publication Date
WO2020123753A2 WO2020123753A2 (fr) 2020-06-18
WO2020123753A3 true WO2020123753A3 (fr) 2020-07-23

Family

ID=69160334

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/065874 WO2020123753A2 (fr) 2018-12-12 2019-12-12 Anellosomes pour l'administration de modalités thérapeutiques intracellulaires

Country Status (11)

Country Link
US (1) US20220040117A1 (fr)
EP (1) EP3894567A2 (fr)
JP (1) JP2022514501A (fr)
KR (1) KR20210131308A (fr)
CN (1) CN114127302A (fr)
AU (1) AU2019396516A1 (fr)
BR (1) BR112021009282A2 (fr)
CA (1) CA3119339A1 (fr)
IL (1) IL283771A (fr)
MX (1) MX2021006941A (fr)
WO (1) WO2020123753A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202334423A (zh) * 2021-12-15 2023-09-01 美商旗艦先鋒創新公司 表面經修飾之病毒顆粒及模組化之病毒顆粒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018232017A1 (fr) * 2017-06-13 2018-12-20 Flagship Pioneering, Inc. Compositions comprenant des curons et leurs utilisations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018232017A1 (fr) * 2017-06-13 2018-12-20 Flagship Pioneering, Inc. Compositions comprenant des curons et leurs utilisations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D. ROHLE ET AL: "An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells", SCIENCE, vol. 340, no. 6132, 3 May 2013 (2013-05-03), pages 626 - 630, XP055078228, ISSN: 0036-8075, DOI: 10.1126/science.1236062 *
NAZISH BOSTAN: "Current and Future Prospects of Torque Teno Virus", JOURNAL OF VACCINES & VACCINATION, 1 January 2013 (2013-01-01), XP055668949, DOI: 10.4172/2157-7560.S1-004 *
RODNEY P. KINCAID ET AL: "A Human Torque Teno Virus Encodes a MicroRNA That Inhibits Interferon Signaling", PLOS PATHOGENS, vol. 9, no. 12, 19 December 2013 (2013-12-19), pages e1003818, XP055139223, ISSN: 1553-7366, DOI: 10.1371/journal.ppat.1003818 *

Also Published As

Publication number Publication date
EP3894567A2 (fr) 2021-10-20
WO2020123753A2 (fr) 2020-06-18
CA3119339A1 (fr) 2020-06-18
AU2019396516A1 (en) 2021-05-27
JP2022514501A (ja) 2022-02-14
CN114127302A (zh) 2022-03-01
BR112021009282A2 (pt) 2021-08-17
IL283771A (en) 2021-07-29
US20220040117A1 (en) 2022-02-10
KR20210131308A (ko) 2021-11-02
MX2021006941A (es) 2021-11-17

Similar Documents

Publication Publication Date Title
MX2022012374A (es) Composiciones multi-suplementos.
MX2018014154A (es) Polinucleotidos moduladores.
CA2956871C (fr) Composes actifs envers des bromodomaines
MX2019015018A (es) Composiciones que comprenden curones y usos de los mismos.
PH12019501970A1 (en) Pharmaceutical compositions for combination therapy
PH12016501578A1 (en) Pharmaceutical compounds
GEP20217239B (en) Pharmaceutical composition
AU2015317715A8 (en) Compositions comprising recombinant Bacillus cells and a fungicide
WO2017223280A3 (fr) Compositions et méthodes de libération d'agents thérapeutiques
MX2021006945A (es) Anelosomas para suministrar modalidades terapéuticas de reemplazo de proteínas.
PH12019501301A1 (en) Pharmaceutical compositions for combination therapy
MX2019008546A (es) Usos terapeuticos de un polvo de insectos.
EP3860585A4 (fr) Compositions thérapeutiques
EP4233880A3 (fr) Compositions de petits arn activateurs de hnf4a et procédés d'utilisation
GEP20217240B (en) Pharmaceutical composition
SG10201900598TA (en) Factor viii formulation
WO2020123773A9 (fr) Anellosomes pour l'administration de modalités thérapeutiques sécrétées
WO2020123816A3 (fr) Anellosomes et méthodes d'utilisation
MX2021006102A (es) Suministro mejorado de agentes grandes.
EP3873444A4 (fr) Composés et compositions thérapeutiques
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
AU2018279184A1 (en) Anti-TrkB antibodies
WO2017161344A8 (fr) Compositions et méthodes pour traiter les parasitoses
WO2020123753A3 (fr) Anellosomes pour l'administration de modalités thérapeutiques intracellulaires

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19836313

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3119339

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021009282

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019396516

Country of ref document: AU

Date of ref document: 20191212

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2021533523

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019836313

Country of ref document: EP

Effective date: 20210712

ENP Entry into the national phase

Ref document number: 112021009282

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210513